Journal of Hematology & Oncology is an open access, peer-reviewed online journal that encompasses all aspects of hematology and oncology. Read more.
Collections open for submissions
- First-in-human clinical trials for cancer and blood disorders
- How we treat
- New developments in delivery technology, materials, and molecular engineering for drug discovery
Deepak Sethi / Getty Images / iStock.
First-in-human clinical trials for cancer and blood disorders
This series calls for clinical studies on novel agents for cancers and blood disorders. Summaries and reviews on first-in-human or first-in-class studies are also welcome.
xixinxing / Fotolia.
How we treat
This series will focus on guidelines, consensus, and multidisciplinary approaches on cancers and blood disorders. All submissions need to be pre-approved. Prospective authors should contact the Editorial Office at Aoife.Buckley@springernature.com with an outline of their paper, the lead author name, and institution.
Manuscripts sponsored by pharmaceutical companies will not be considered.
weyo / stock.adobe.com
New developments in delivery technology, materials, and molecular engineering for drug discovery
This series covers new technology, materials, and models for drug discovery. Development and applications of organoids, 3D cultures, PDX modes, nano-molecules, AI technology, and single-cell maps for drug discovery will be the focus.
Aims and scope
Experimental Hematology & Oncology
Submit your research to our companion journal, Experimental Hematology & Oncology
Articles
-
-
The regulation of insulin receptor/insulin-like growth factor 1 receptor ratio, an important factor for breast cancer prognosis, by TRIP-Br1
-
Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients
-
Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence
-
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation
-
Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options
-
The effects of β-glucan on human immune and cancer cells
-
The diagnosis and management of NK/T-cell lymphomas
-
Mechanism of action of lenalidomide in hematological malignancies
-
SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19
Springer Nature Oncology Portfolio
Discover the range of academic oncology titles at Springer Nature here.
CAHON: Stop hate crimes and racism
The Chinese American Hematologist and Oncologist Network (CAHON) has published an important and timely Editorial in the Journal of Hematology & Oncology. We are proud to stand with them in denouncing in the strongest terms all forms of discrimination and crimes against any racial/ethnic group, including Asian Americans and Pacific Islanders, and to call on our readers to pursue racial equality and tolerance in the USA and beyond.
Editor's quote
"Journal of Hematology & Oncology provides a forum for top-quality research and is a leading title in hematology and oncology, with an Impact Factor ranked in Q1 in both categories. The journal also publishes reviews and research highlights from leading experts in the field. Research is shared with fast turnaround times in an open access format among laboratory scientists, physician scientists, hematologists and oncologists."
Prof Delong Liu, Editor-in-Chief, Journal of Hematology & Oncology
Latest Tweets
View Twitter timeline
Your browser needs to have JavaScript enabled to view this timeline
-
Official journal of
-
Journal of Hematology & Oncology is the official journal of the Chinese American Hematologist and Oncologist Network.
-
- Editorial Board
- Instructions for Editors
- Instructions for authors
- Sign up for article alerts and news from this journal
Follow
Annual Journal Metrics
-
Speed
5 days to first decision for all manuscripts
36 days to first decision for reviewed manuscripts only
69 days from submission to acceptance
20 days from acceptance to publication
Citation Impact
17.388 - 2-year Impact Factor
12.642 - 5-year Impact Factor
2.741 - Source Normalized Impact per Paper (SNIP)
4.305 - SCImago Journal Rank (SJR)
Usage
2,370,051 Downloads (2021)
1153 Altmetric Mentions
On the blog
-
Cancer champions – to the local community center… and beyond!
03 February 2022
-
-
Screening for kidney cancer in Leeds
16 April 2021
Institutional membership
Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).